Unknown PHASE2 INTERVENTIONAL 2-arm NCT03736616

Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Acalabrutinib Plus RICE for Patients With Relapsed/Refractory DLBCL Followed by Autologous Hematopoietic Cell Transplantation and Acalabrutinib Maintenance Therapy

Sponsor: Acerta Pharma BV

Conditions Diffuse Large B Cell Lymphoma

Interventions Acalabrutinib Autologous HSCT Carboplatin Carmustine Cytarabine Etoposide Ifosfamide Melphalan Rituximab

Updated 8 times since 2018 Last updated: Jul 20, 2022 Started: Aug 16, 2019 Primary completion: Sep 30, 2023 Completion: Sep 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03736616, this PHASE2 trial focuses on Diffuse Large B Cell Lymphoma and remains ongoing. Sponsored by Acerta Pharma BV, it has been updated 8 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2021 — Sep 2022 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2018 — Feb 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acerta Pharma BV
Swedish Medical Center

Data source: Swedish Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States